Immunologic and Predictive Features of MIS-C
MIS-C 的免疫学和预测特征
基本信息
- 批准号:10667530
- 负责人:
- 金额:$ 57.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-18 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAcuteAdultAgeAlgorithmsAntibody RepertoireAreaAutoantibodiesBiologicalBiological AssayBiological MarkersBloodCOVID-19COVID-19 mortalityCOVID-19 pandemicCellsCellular Indexing of Transcriptomes and Epitopes by SequencingCharacteristicsChildChild DevelopmentChildhoodClinicalComputer ModelsCritical CareDataData CollectionData SetDevelopmentDiagnosisDiseaseDisease OutbreaksFunctional disorderGeneticGenomicsImmuneImmunologicsImmunophenotypingIndividualInfectionInflammationInflammatoryInfluenza A virusInfluenza B VirusInstitutional Review BoardsLifeLondonMachine LearningMapsMeasurementModelingMononuclearMorbidity - disease rateMucocutaneous Lymph Node SyndromeMultisystem Inflammatory Syndrome in ChildrenNew York CityOutcomePathogenesisPatientsPhasePneumoniaPrognosisPublishingRelative RisksReportingRespiratory DiseaseRiskRisk AssessmentSARS coronavirusSARS-CoV-2 antibodySARS-CoV-2 infectionSARS-CoV-2 positiveSamplingSerologyShockSiteSpainSurfaceSymptomsSyndromeTechnologyTimeVirusWorld Health Organizationbiomarker identificationclinical centercohortcomparison controlcoronavirus diseasedisease diagnosisdisease prognosisdisorder riskearly childhoodexome sequencingfollow-upimprovedinfection ratelong-term sequelaemachine learning algorithmmachine learning methodnovelpathogenpediatric patientspost SARS-CoV-2 infectionrecruitrisk predictionrisk stratificationrisk variantsingle-cell RNA sequencing
项目摘要
The novel SARS coronavirus (SARS-CoV-2) causes the severe pneumonia-like coronavirus
disease (COVID-19). SARS-CoV-2 infected over 170 million individuals and has claimed over
3.5 million lives worldwide to date. If otherwise healthy, children were thought to be largely
spared from SARS-CoV-2 disease. However, in areas of high SARS-CoV-2 infection rates,
some children started presenting to pediatric critical care units 4-6 weeks following SARS-CoV-
2 infection with Kawasaki-like disease. Clinically, we now know that this is a distinct disease,
which was recently termed - multisystem inflammatory syndrome in children (MIS-C). While the
characteristic clinical features of MIS-C are becoming clear, the pathophysiology remains
unknown. Here we propose to evaluate three independent cohorts of MIS-C during acute and
convalescent phases of disease at clinical, genetic and immunologic levels using the latest
technology. We will not only perform systemic immunological mapping of MIS-C as compared to
controls, but also utilize machine learning algorithms to delineate how best to predict, diagnose
and outcome stratify MIS-C. We anticipate discovering immunologic and genetic features which
can aid us in assessing risks of MIS-C development, diagnosis and prognosis. In summary, our
systematic analysis and computational modeling of the clinical and immune features of MIS-C
will not only help illuminate the pathogenesis of this syndrome, but will also provide us with
actionable biomarkers for disease risk, diagnosis and progression.
新型 SARS 冠状病毒(SARS-CoV-2)引起严重的肺炎样冠状病毒
疾病(COVID-19)。 SARS-CoV-2 感染了超过 1.7 亿人,并已导致超过
迄今为止,全世界有 350 万人生活在其中。如果其他方面健康的话,儿童被认为在很大程度上是
免受 SARS-CoV-2 疾病的侵害。然而,在 SARS-CoV-2 感染率高的地区,
一些儿童在 SARS-CoV 感染后 4-6 周开始到儿科重症监护室就诊
2.感染川崎病样病。在临床上,我们现在知道这是一种独特的疾病,
最近被称为儿童多系统炎症综合征(MIS-C)。虽然
MIS-C 的典型临床特征正在变得清晰,但病理生理学仍然存在
未知。在这里,我们建议评估急性和急性期 MIS-C 的三个独立队列。
使用最新的临床、遗传和免疫水平的疾病恢复期
技术。我们不仅会进行 MIS-C 的系统免疫图谱分析,
控制,还利用机器学习算法来描述如何最好地预测、诊断
和结果分层 MIS-C。我们期望发现免疫学和遗传特征
可以帮助我们评估 MIS-C 发生、诊断和预后的风险。综上所述,我们的
MIS-C 临床和免疫特征的系统分析和计算建模
不仅有助于阐明该综合征的发病机制,而且还将为我们提供
用于疾病风险、诊断和进展的可行生物标志物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dusan Bogunovic其他文献
Dusan Bogunovic的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dusan Bogunovic', 18)}}的其他基金
New York Regional Inborn Errors of Immunity Resource Initiative League (NY-ROYAL)
纽约地区先天性缺陷免疫资源倡议联盟 (NY-ROYAL)
- 批准号:
10554965 - 财政年份:2023
- 资助金额:
$ 57.43万 - 项目类别:
Transient Gene Therapy as Broad Spectrum Antiviral
瞬时基因疗法作为广谱抗病毒药物
- 批准号:
10324302 - 财政年份:2021
- 资助金额:
$ 57.43万 - 项目类别:
Role of SARS-CoV-2-mediated Type I IFN antagonism in individuals with Down Syndrome
SARS-CoV-2 介导的 I 型 IFN 拮抗作用在唐氏综合症患者中的作用
- 批准号:
10158984 - 财政年份:2020
- 资助金额:
$ 57.43万 - 项目类别:
Inborn Errors of Immunity Leading to Autoinflammatory Syndromes
先天性免疫缺陷导致自身炎症综合征
- 批准号:
10206016 - 财政年份:2020
- 资助金额:
$ 57.43万 - 项目类别:
Inborn Errors of Immunity Leading to Autoinflammatory Syndromes
先天性免疫缺陷导致自身炎症综合征
- 批准号:
10058607 - 财政年份:2020
- 资助金额:
$ 57.43万 - 项目类别:
Next Generation Resolution of Antiviral Gene Networks
抗病毒基因网络的下一代解决方案
- 批准号:
10120982 - 财政年份:2020
- 资助金额:
$ 57.43万 - 项目类别:
Inborn Errors of Immunity Leading to Autoinflammatory Syndromes
先天性免疫缺陷导致自身炎症综合征
- 批准号:
10443794 - 财政年份:2020
- 资助金额:
$ 57.43万 - 项目类别:
Inborn Errors of Immunity Leading to Autoinflammatory Syndromes
先天性免疫缺陷导致自身炎症综合征
- 批准号:
10655435 - 财政年份:2020
- 资助金额:
$ 57.43万 - 项目类别:
Next Generation Resolution of Antiviral Gene Networks
抗病毒基因网络的下一代解决方案
- 批准号:
10461962 - 财政年份:2020
- 资助金额:
$ 57.43万 - 项目类别:
Next Generation Resolution of Antiviral Gene Networks
抗病毒基因网络的下一代解决方案
- 批准号:
10681411 - 财政年份:2020
- 资助金额:
$ 57.43万 - 项目类别:
相似海外基金
Un/kindness, shame & resistance: the care of inpatients in NHS adult acute mental health units and how it might be improved
Un/善良,羞耻
- 批准号:
2885806 - 财政年份:2023
- 资助金额:
$ 57.43万 - 项目类别:
Studentship
Post-Acute Care Transitions for Older Adult Medicare Beneficiaries with Serious Mental Illness
患有严重精神疾病的老年医疗保险受益人的急性后护理过渡
- 批准号:
10772386 - 财政年份:2023
- 资助金额:
$ 57.43万 - 项目类别:
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
通过 CAR-T 细胞疗法为加拿大护理标准铺平道路:CD19 CAR-T 治疗复发/难治性成人急性淋巴细胞白血病的 II 期试验 (CLIC-01A)
- 批准号:
474619 - 财政年份:2022
- 资助金额:
$ 57.43万 - 项目类别:
Operating Grants
Investigating the impact acute inhalation of cannabis with a high content of delta-9-tetrahydrocannabinol has on myelination and microglia in adult and aged mice
研究急性吸入高含量 delta-9-四氢大麻酚的大麻对成年和老年小鼠髓鞘形成和小胶质细胞的影响
- 批准号:
485965 - 财政年份:2022
- 资助金额:
$ 57.43万 - 项目类别:
Studentship Programs
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
通过 CAR-T 细胞疗法为加拿大护理标准铺平道路:CD19 CAR-T 治疗复发/难治性成人急性淋巴细胞白血病的 II 期试验 (CLIC-01A)
- 批准号:
466358 - 财政年份:2022
- 资助金额:
$ 57.43万 - 项目类别:
Operating Grants
Metabolomics for prediction of cisplatin mediated acute kidney injury: a Canadian multi-centre adult and pediatric study
预测顺铂介导的急性肾损伤的代谢组学:加拿大多中心成人和儿童研究
- 批准号:
402040 - 财政年份:2019
- 资助金额:
$ 57.43万 - 项目类别:
Operating Grants
Study of pathogenic mechanism of age-dependent chromosome translocation in adult acute lymphoblastic leukemia
成人急性淋巴细胞白血病年龄依赖性染色体易位发病机制研究
- 批准号:
18K16103 - 财政年份:2018
- 资助金额:
$ 57.43万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Causal effect of time-varying driving pressures on mortality in mechanically ventilated, adult patients with acute respiratory distress syndrome
时变驱动压力对机械通气成年急性呼吸窘迫综合征患者死亡率的因果影响
- 批准号:
377313 - 财政年份:2017
- 资助金额:
$ 57.43万 - 项目类别:
Studentship Programs
Role of SETBP1 in adult Ph+ acute lymphoblastic leukemia
SETBP1 在成人 Ph 急性淋巴细胞白血病中的作用
- 批准号:
9315111 - 财政年份:2016
- 资助金额:
$ 57.43万 - 项目类别:
Acute Inhibition of Adult-born Granule Cells and its Effect on Antidepressant Act
成体颗粒细胞的急性抑制及其抗抑郁作用
- 批准号:
8734273 - 财政年份:2013
- 资助金额:
$ 57.43万 - 项目类别:














{{item.name}}会员




